SCHEMBL6574404

SCHEMBL6574404

CC(C)=CC(=O)Nc1cccc(Br)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.69
KMT2A Q03164 1/20 0.69
TGM2 P21980 1/20 0.66
SMN1; SMN2 Q16637 5/20 0.65
RAB9A P51151 4/20 0.65
NPC1 O15118 3/20 0.65
TSHR P16473 1/20 0.65
NFKB1 P19838 1/20 0.65
NFKB2 Q00653 1/20 0.65
RELA Q04206 1/20 0.65
MAOB P27338 6/20 0.57
MAOA P21397 4/20 0.57
GAA P10253 2/20 0.57
HTT P42858 1/20 0.51
PARP1 P09874 1/20 0.51
PARP15 Q460N3 1/20 0.51
PARP10 Q53GL7 1/20 0.51
ALDH1A1 P00352 2/20 0.50
TP53 P04637 2/20 0.50
HPGD P15428 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11679433 0.86 TGM2 (0.60) MEN1KMT2ATGM2SMN1; SMN2RAB9A
SCHEMBL11679437 0.86 TGM2 (0.60) MEN1KMT2ATGM2SMN1; SMN2RAB9A
SCHEMBL9312293 0.83 MEN1 (0.73) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL11754128 0.81 KMT2A (1.00) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL17150833 0.81 KMT2A (0.71) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL264735 0.80 GAA (0.66) TGM2SMN1; SMN2RAB9ANPC1GAA
SCHEMBL23674672 0.80 MEN1 (0.69) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL26697030 0.80 MEN1 (0.69) MEN1KMT2ATGM2SMN1; SMN2RAB9A
SCHEMBL1381249 0.79 TGM2 (1.00) TGM2MAOBMAOAGAAEGFR
SCHEMBL29505044 0.79 TGM2 (1.00) TGM2MAOBMAOAGAAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118164955-A Novel acaricide and preparation method thereof 山东中新科农生命科技股份有限公司 2024-06-11 CN disclosed
EP-0937045-B1 N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY ALLERGAN INC (US) 2004-04-28 EP disclosed
EP-0937045-A1 N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY Allergan Sales, Inc. (US) 1999-08-25 EP disclosed
WO-1998019999-A1 N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY ALLERGAN SALES, INC. (US) 1998-05-14 WO disclosed
US-5739338-A SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS, VISION DEFECTS, VIRICIDES, IMMUNOSUPPRESSANTS ALLERGAN (US) 1998-04-14 US disclosed
EP-0825986-A1 QUINOLYL-ETHYNYL DERIVATIVES HAVING RETINOID-LIKE ACTIVITY Allergan (US) 1998-03-04 EP disclosed
US-5616712-A SKIN DISORDERS; ANTICARCINOGENIC AND -INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; ALLERGAN (US) 1997-04-01 US disclosed
WO-1996036609-A1 QUINOLYL-ETHYNYL DERIVATIVES HAVING RETINOID-LIKE ACTIVITY ALLERGAN (US) 1996-11-21 WO disclosed
EP-0350846-B1 Condensed heterocyclic compounds and their use in therapy HOFFMANN LA ROCHE (CH) 1995-10-11 EP disclosed
US-5420273-A Skin disorders and antitumor agents HOFFMAN-LA ROCHE INC. (US) 1995-05-30 US disclosed
US-5300522-A Treating inflammatory, allergic, rheumatic, immunological disorders HOFFMANN-LA ROCHE INC. (US) 1994-04-05 US disclosed
US-5216148-A Treating, preventing neoplasms, dermatoses, aging of skin HOFFMANN-LA ROCHE INC. (US) 1993-06-01 US disclosed
US-5164387-A Antitumor agents, skin disorders, antiinflammatory agents HOFFMANN-LAROCHE INC. (US) 1992-11-17 US disclosed
EP-0504695-A1 New carboxamides, their preparation and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE AG (CH) 1992-09-23 EP disclosed
US-5037825-A Useful In The Treatment Of Neoplasms, Dermatoses And Aging Of The Skin HOFFMANN-LA ROCHE INC. (US) 1991-08-06 US disclosed
EP-0350846-A2 Condensed heterocyclic compounds and their use in therapy F. HOFFMANN-LA ROCHE AG (CH) 1990-01-17 EP disclosed